Clinical impact of BRAF mutation on the diagnosis and prognosis of papillary thyroid carcinoma: a systematic review and meta‐analysis

Abstract

BRAF(V) (600E) mutation analysis can not only be used in the diagnosis of PTC, but can also predict its prognosis.

High prevalence of BRAF V600E mutations in Korean patients with ameloblastoma: Clinicopathological significance and correlation with epithelial‐mesenchymal transition

“…Mutations in the MAPK pathway are considered potential therapeutic targets for cancer treatment. BRAF inhibitors (eg, PLX4032 [vemurafenib], PLX4720, and GSK2118436 [dabrafenib]) and MEK inhibitors (eg, GSK1120212 [trametinib]) have been developed and investigated to assess the inhibitory effects in cancers frequently harboring BRAF V600E mutations, such as melanoma and PTC . In the same manner, the efficacy of MAPK pathway inhibitors in BRAF V600E‐mutant ameloblastoma has been tested in pre‐clinical studies and clinical trials .…”

“…Raf proteins are highly conserved serine/threonine kinases of the MAPK pathway and activating mutations in the RAF gene may induce persistent activation of MAPK cascades, resulting in tumorigenesis . Among these mutations, BRAF V600E, which is caused by a missense mutation T1799A, is most commonly found in human tumors, especially papillary thyroid carcinoma (PTC), melanoma, and colorectal cancer . Over the past few years, BRAF V600E mutations have also been detected at a high frequency in ameloblastoma, the most common and clinically significant epithelial odontogenic tumor, but their prevalence has not yet been reported in East Asian patients with ameloblastoma.…”

Analysis of circulating tumor DNA does not improve the clinical management of patients with locally advanced and metastatic papillary thyroid carcinoma

“…The BRAF mutations in PTCs, in particular the V600E, are associated with clinical‐pathological features of tumor aggressiveness, as advanced stage, extrathyroidal invasion, and regional lymph node metastasis. Moreover several studies demonstrated a correlation between BRAF V600E and a poorer overall survival . The use of BRAF V600E as a circulating marker could have important clinical application in the management of patients with thyroid cancer.…”

“…Moreover several studies demonstrated a correlation between BRAF V600E and a poorer overall survival. 18,19 The use of BRAF V600E as a circulating marker could have important clinical application in the management of patients with thyroid cancer. This might allow the diagnosis of some patients with PTC with a less invasive test and help to identify patients with unrecognized postoperative minimal residual disease.…”

The usefulness of a novel fully automated PCR-based Idylla test for detection of the BRAF V600E mutation in thyroid tissue: comparison with PNA-clamping PCR, real-time PCR and pyrosequencing

“…Although thyroid carcinoma is one of the most indolent tumours, approximately 8%–30% of PTC undergo recurrence or metastasis 10 11. The BRAF V600E mutational status has shown a significant diagnostic, prognostic and therapeutic role in PTC 12. High prevalence of a BRAF V600E mutation in PTC, especially in Korean patients, makes it an attractive target for evaluating the BRAF V600E mutational status and clinical significance in PTC 13 14…”